𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tetrabenazine in the treatment of severe pediatric chorea

✍ Scribed by Anjan Chatterjee; Steven J. Frucht

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
58 KB
Volume
18
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Tetrabenazine (TBZ) is widely used to treat adults with hyperkinetic movement disorders; however, published experience with the drug in pediatric patients is limited. We report on 5 children with severe chorea who were treated with TBZ. TBZ effectively controlled chorea in 4 patients, and despite the need for relatively high doses, it was well tolerated. Β© 2003 Movement Disorder Society

πŸ“œ SIMILAR VOLUMES

Anticholinergic-induced chorea in the tr
Anticholinergic-induced chorea in the treatment of focal dystonia
✍ M. Nomoto; P. D. Thompson; M. P. Sheehy; N. P. Quinn; C. D. Marsden πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 208 KB

The occurrence of chorea, induced by trihexyphenidyl (benzhexol hydrochloride) during the treatment of five adult patients who had focal or segmental dystonia, is described. The dose at which chorea appeared ranged from 15 to 60 mg/day (mean 31.7 mglday). All but one patient had developed common adv

Long-term tolerability of tetrabenazine
Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
✍ Christopher Kenney; Christine Hunter; Joseph Jankovic πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 90 KB πŸ‘ 1 views

## Abstract We sought to review the long‐term tolerability of tetrabenazine (TBZ) and seek determinants of tolerability in the treatment of hyperkinetic movement disorders. A retrospective chart review was performed on patients treated with TBZ between 1997 and 2004. Efficacy of TBZ was assessed by

Treatment of the symptoms of Huntington'
Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine
✍ Livia Brusa; Antonio Orlacchio; Vincenzo Moschella; Cesare Iani; Giorgio Bernard πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 438 KB

## Abstract Aripiprazole (AP), a dopamine (DA) D~2~ receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD). The aim of this study is to define the role of AP on ch